Very detailed and indepth coverage on Neuland by BK
Some takeaways:
- CMS revenues will only go up from here
- Big supplies for Karuna will start after approval which is due in Sep’24
- Supplies to Esperion will go up
- Peptides things are slow but on track
- Capex as planned
- Aggressive hirings at R&D level
| Subscribe To Our Free Newsletter |
